NCT04864067 (NOAHS-ARC) is a Phase 2 clinical trial of Oxaliplatin in Rectal Cancer, sponsored by Servicio de Salud Metropolitano Sur Oriente.

Who is sponsoring NCT04864067?

NCT04864067 is sponsored by Servicio de Salud Metropolitano Sur Oriente.

What drugs are being tested in NCT04864067?

Interventions in NCT04864067: Oxaliplatin, 5-Fluoracil, Leucovorin, Capecitabine, 5x5 Gy, Quality of Life Questionnaires, DRE/ Endoscopy.

What condition does NCT04864067 study?

NCT04864067 studies Rectal Cancer.

Is NCT04864067 still recruiting?

NCT04864067 is currently active, enrolled. Last updated 1 July 2025.

Last reviewed 2025-07-01 · How we verify

NCT04864067: NOAHS-ARC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer

Active, enrolled Phase 2 Last updated 1 July 2025

What this trial tests

Phase 2 trial testing Oxaliplatin in Rectal Cancer in 73 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 June 2021

Primary endpoint
1 December 2025

1 March 2026

Quick facts

Lead sponsor	Servicio de Salud Metropolitano Sur Oriente
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	73
Start date	9 June 2021
Primary completion	1 December 2025
Estimated completion	1 March 2026
Sites	3 locations across Chile

Drugs / interventions tested

Oxaliplatin (Oxaliplatin) — full drug profile →
5-Fluoracil
Leucovorin (leucovorin) — full drug profile →
Capecitabine (capecitabine) — full drug profile →
5x5 Gy
Quality of Life Questionnaires
DRE/ Endoscopy

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Servicio de Salud Metropolitano Sur Oriente — full company profile →

Who can join

18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by neoadjuvant consolidation chemotherapy is associated with a higher rate of pathological clinical response and sustained (\>1year) complete clinical response when compared to an historical cohort treated with long course chemoradiation therapy (CRT), total mesorectal excision (TME) and adjuvant chemotherapy (ACT).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

No operation after short-course radiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer (NOAHS-ARC): study protocol for a prospective, phase II trial.
Quezada-Díaz FF, Bercz A, Escobar JL, Caire N, et al · · 2025 · cited 1× · PMID 40100473 · DOI 10.1007/s00384-025-04850-9
No Operation After Short-Course Radiotherapy Followed By Consolidation Chemotherapy in Locally Advanced Rectal Cancer (NOAHS-ARC): Study Protocol for a Prospective, Phase II Trial
Quezada-Díaz FF, Bercz A, Romesser PB, Escobar JL, et al · · 2024 · DOI 10.21203/rs.3.rs-4713792/v1

Verify or expand the search:

Other trials of Oxaliplatin

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04864067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Servicio de Salud Metropolitano Sur Oriente
Last refreshed: 1 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04864067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing